Dydrogesterone in threatened miscarriage: A Malaysian experience

Maturitas

Volumn 65, Issue SUPPL. 1, 2009, Pages

  Pandian, Ramachandhiran Udayar ^a  

^a Seberang Jaya Hospital   (Malaysia)

Author keywords

Dydrogesterone; Malaysia; Pregnancy; Progestogen; Threatened miscarriage

Indexed keywords

DYDROGESTERONE;

ADULT; ANTEPARTUM HEMORRHAGE; ARTICLE; CESAREAN SECTION; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFECT; FEMALE; HUMAN; IMMINENT ABORTION; INTERMETHOD COMPARISON; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MALAYSIA; MATERNAL HYPERTENSION; MONOTHERAPY; PATIENT SATISFACTION; PLACENTA PREVIA; PREGNANCY; PREMATURE LABOR; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; VAGINA BLEEDING;

ABORTION, HABITUAL; ABORTION, SPONTANEOUS; ABORTION, THREATENED; ADULT; BED REST; DYDROGESTERONE; FEMALE; HUMANS; MALAYSIA; PREGNANCY; PROGESTINS; PROSPECTIVE STUDIES; REPRODUCTIVE CONTROL AGENTS; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 72649089521     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.11.016     Document Type: Article

References (31)

1. Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ 315 (1997) 32-34
2. Stabile I., Cambell S., and Grudinskas J. Ultrasound assessment of complications during first trimester of pregnancy. Lancet 2 (1987) 1237-1240
3. Weiss J.L., Malone F.D., Vidaver J., et al. Threatened abortion: a risk factor for poor pregnancy outcome, a population-based screening study. Am J Obstet Gynecol 190 (2004) 745-750
4. Sotiriadis A., Papatheodorou S., and Makrydimas G. Threatened miscarriage: evaluation and management. BMJ 329 (2004) 152-155
5. Cunningham G., Leveno K.J., Bloom S.L., and Hauth J.C. Physiology of pregnancy. Williams obstetrics. 21st ed. (2005), McGraw-Hill, New York
6. Schindler A.E. First trimester endocrinology: consequences for diagnosis and treatment of pregnancy failure. Gynecol Endocrinol 18 (2004) 51-57
7. Szekeres-Bartho J., Barakonyi A., Polgar B., et al. The role of gamma/delta T cells in progesterone-mediated immunomodulation during pregnancy: a review. Am J Reprod Immunol 42 (1999) 44-48
8. Hidalgo A., Suzano R.C., Revuelta M.P., Sanchez-Diaz C., Baamonde A., and Cantabrana B. Calcium and depolarization-dependent effect of pregnenolone derivatives on uterine smooth muscle. Gen Pharmacol 27 (1996) 879-885
9. Wahabi H.A., Abed Althagafi N.F., and Elawad M. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev July (2007) CD005943
10. Schindler A.E., Campagnoli C., Druckmann R., et al. Classification and pharmacology of progestins. Maturitas 46 Suppl. 1 (2003) S7-16
11. Omar M.H., Mashita M.K., Lim P.S., and Jamil M.A. Dydrogesterone in threatened abortion: pregnancy outcome. J Steroid Biochem Mol Biol 97 (2005) 421-425
12. Pelinescu-Onciul D. Subchorionic hemorrhage treatment with dydrogesterone. Gynecol Endocrinol 23 Suppl. 1 (2007) 77-81
13. Kalinka J., and Szekeres-Bartho J. The impact of dydrogesterone supplementation on hormonal profile and progesterone-induced blocking factor concentrations in women with threatened abortion. Am J Reprod Immunol 53 (2005) 166-171
14. Czajkowski K., Sienko J., Mogilinski M., Bros M., Szczecina R., and Czajkowska A. Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone. Fertil Steril 87 (2007) 613-618
15. Szekeres-Bartho J., Wilczynski J.R., Basta P., and Kalinka J. Role of progesterone and progestin therapy in threatened abortion and preterm labour. Front Biosci 13 (2008) 1981-1990
16. Polgár B., Nagy E., Mikó E., Varga P., and Szekeres-Barthó J. Urinary progesterone-induced blocking factor concentration is related to pregnancy outcome. Biol Reprod 71 (2004) 1699-1705
17. Raghupathy R., Al Mutawa E., Makhseed M., Azizieh F., and Szekeres-Bartho J. Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent miscarriage. BJOG 112 (2005) 1096-1101
18. Raghupathy R., Al Mutawa E., Makhseed M., Al-Azemi M., and Azizieh F. Redirection of cytokine production by lymphocytes from women with pre-term delivery by dydrogesterone. Am J Reprod Immunol 58 (2007) 31-38
19. Orsal A.S., Blois S., Labuz D., Peters E.M., Schaefer M., and Arck P.C. The progesterone derivative dydrogesterone down-regulates neurokinin 1 receptor expression on lymphocytes, induces a Th2 skew and exerts hypoalgesic effects in mice. J Mol Med 84 (2006) 159-167
20. Blois S.M., Joachim R., Kandil J., et al. Depletion of CD8+ cells abolishes the pregnancy protective effect of progesterone substitution with dydrogesterone in mice by altering the Th1/Th2 cytokine profile. J Immunol 172 (2004) 5893-5899
21. Joachim R., Zenclussen A.C., Polgar B., et al. The progesterone derivative dydrogesterone abrogates murine stress-triggered abortion by inducing a Th2 biased local immune response. Steroids 68 (2003) 931-940
22. Simoncini T., Caruso A., Giretti M.S., et al. Effects of dydrogesterone and of its stable metabolite, 20-alpha-dihydrodydrogesterone, on nitric oxide synthesis in human endothelial cells. Fertil Steril 86 4 Suppl. (2006) 1235-1242
23. Sladek S.M., Magness R.R., and Conrad K.P. Nitric oxide and pregnancy. Am J Physiol 272 (1997) R441-R463
24. Goujard J., and Rumeau-Rouquette C. First trimester exposure to progestagen/oestrogen and congenital malformations. Lancet I (1977) 482-483
25. Nora J.J., Nora A.H., Blu J., et al. Exogenous progestogen and estrogen implicated in birth defects. JAMA 240 (1978) 837-843
26. Wilson J.G., and Brent R.L. Are female sex hormones teratogenic?. Am J Obstet Gynecol 141 (1981) 567-580
27. Resseguie L.J., Hick J.F., Bruen J.A., Noller K.L., O'Fallon W.M., and Kurland L.T. Congenital malformations among offspring exposed in utero to progestins, Omsted County, Minnesota 1936-1974. Fertil Steril 43 (1985) 514-519
28. Katz Z., Lancet M., Skornik J., Chemke J., Mogilner B.M., and Klinberg M. Teratogenicity of progestogens given during the first trimester of pregnancy. Obstet Gynecol 65 (1985) 775-780
29. Martínez-Frías M.L., Rodríguez-Pinilla E., and Bermejo E. Prenatal exposure to sex hormones: a case control study. Teratology 57 (1998) 8-12
30. Raman-Wilms L., Tseng A.L., Wighardt S., Einarson T.R., and Koren G. Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis. Obstet Gynecol 85 (1995) 141-149
31. Queisser-Luft A. Dydrogesterone use during pregnancy: overview of birth defects reported since 1977. Early Hum Dev 85 (2009) 375-377